This week Alex and James are joined by Gian Seehra an investor at Octopus Ventures to talk about transitioning from entrepreneur to venture capital, health tech investments and how both founders and investors should approach setting early valuations.
Gian focuses on health investments at Octopus and splits his time on deal origination and assessment of investment opportunities. Prior to joining Octopus, Gian spent two years in Canada building a biotechnology company called Pebble Labs tackling vector-borne, animal and plant diseases, and Trait Biosciences within the cannabis industry.
Gian holds a degree in Industrial Economics from the University of Nottingham. He spent two months training in Muay Thai Boxing in Thailand and plans to spend two weeks a year training there.
Octopus Ventures are one of Europe’s largest Venture Capital teams with £1bn under management. Octopus is a generalist fund but with specialist investments in health-tech. Based in London and New York, they have Venture Partners in San Francisco, Singapore and China. Their typical initial investment is from £1m for Seed to around £5m for Series A.